{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:35:10Z","timestamp":1794123310558,"version":"4.8.0"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2019,1,30]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Malignant pleural effusion, which is a common clinical problem in patients with cancer, may be due to both primary thoracic tumours or to a metastatic spread in the chest and constitutes the first sign of disease in approximately 10% of patients. Almost all cancers can potentially produce a pleural effusion. The presence of malignant tumour cells in the pleural fluid is generally indicative of advanced disease and is associated with high morbidity and mortality with reduced therapeutic options. Dyspnoea during mild physical activity or at rest is generally the typical sign of restrictive respiratory failure. &lt;\/P&gt;&lt;P&gt; Methods: This is a systematic review of all the main articles in the English language on the topic of malignant pleural effusion and reported by the Pubmed database from 1959 to 2018. I reviewed the literature and guidelines with the aims to focus on what is known and on future pathways to follow the diagnosis and treatment of malignant pleural effusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The main goal of palliation of a malignant pleural effusion is a quick improvement in dyspnoea, while thoracentesis under ultrasound guidance is the treatment of choice for patients with a limited life expectancy or who are not candidates for more invasive procedures such as drainage using an indwelling small pleural catheter, chemical pleurodesis with sclerosing agents, pleurectomy or pleuro-peritoneal shunt.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Despite progress in therapeutic options, the prognosis remains severe, and the average survival is 4-9 months from the diagnosis of malignant pleural effusion. Moreover, mortality is higher for patients with malignant pleural effusion compared with those with metastatic cancer but no malignant pleural effusion. Therefore, the prognosis of these patients primarily depends on the underlying disease and the extension of a primary tumour. This review focuses on the most relevant updates in the management of malignant pleural effusion.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574887114666181204105208","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T12:09:55Z","timestamp":1543925395000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Malignant Pleural Effusion: Still a Long Way to Go"],"prefix":"10.2174","volume":"14","author":[{"given":"Fausto","family":"Meriggi","sequence":"first","affiliation":[{"name":"Oncology Department - Poliambulanza Foundation, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","volume":"162","year":"2000","unstructured":". Management of malignant pleural effusions.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1378\/chest.49.1.67","volume":"49","author":"Cohen S.","year":"1966","unstructured":"Cohen S, Hossain SA. Primary carcinoma of the lung: A review of 417 histologically proved cases.","journal-title":"Dis Chest"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0096-5588(20)30058-1","volume":"37","author":"Emerson G.L.","year":"1959","unstructured":"Emerson GL, Emerson MS, Sherwood CE. The natural history of carcinoma of the lung.","journal-title":"J Thorac Surg"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/1097-0142(19850815)56:4<905::AID-CNCR2820560435>3.0.CO;2-U","volume":"56","author":"Johnston W.W.","year":"1985","unstructured":"Johnston WW. The malignant pleural effusion: A review of cytopathologic diagnosis of 584 specimens from 472 consecutive patients.","journal-title":"Cancer"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0002-9343(83)91072-0","volume":"74","author":"Estenne M.","year":"1983","unstructured":"Estenne M, Yernault JC, De Troyer A. Mechanism of relief of dyspnoea after thoracocentesis in patients with large pleural effusions.","journal-title":"Am J Med"},{"key":"ref=6","first-page":"658","volume":"133","author":"Light R.W.","year":"1986","unstructured":"Light RW, Stansbury DW, Brown SE. The relationship between pleural pressures and changes in pulmonary function after therapeutic thoracentesis.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1378\/chest.111.4.970","volume":"111","author":"Heffner J.","year":"1997","unstructured":"Heffner J, Brown L, Barbieri C. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators.","journal-title":"Chest"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0025-6196(11)60848-3","volume":"83","author":"Heffner J.E.","year":"2008","unstructured":"Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions.","journal-title":"Mayo Clin Proc"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1378\/chest.08-3002","volume":"137","author":"Heffner J.E.","year":"2010","unstructured":"Heffner JE, Klein JS, Hampson C. Diagnostic utility and clinical application of imaging for pleural space infections.","journal-title":"Chest"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpainsymman.2005.01.015","volume":"30","author":"Marrazzo A.","year":"2005","unstructured":"Marrazzo A, Noto A, Casa L. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: The importance of an early intervention.","journal-title":"J Pain Symptom Manage"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/1817-1737.197762","volume":"12","author":"Ferreiro L.","year":"2017","unstructured":"Ferreiro L, Su\u00e1rez-Antelo J, Vald\u00e9s L. Pleural procedures in the management of malignant effusions.","journal-title":"Ann Thorac Med"},{"key":"ref=12","first-page":"5131","volume":"32","author":"Basso S.M.","year":"2012","unstructured":"Basso SM, Mazza F, Marzano B. Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.","journal-title":"Anticancer Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"Roberts M.E.","year":"2010","unstructured":"Roberts ME, Neville E, Berrisford RG. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010.","journal-title":"Thorax"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MCP.0b013e3283615b67","volume":"19","author":"Davies H.E.","year":"2013","unstructured":"Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers.","journal-title":"Curr Opin Pulm Med"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.chest.2017.08.026","volume":"153","author":"Ost D.E.","year":"2018","unstructured":"Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions.","journal-title":"Chest"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.6004\/jnccn.2012.0102","volume":"10","author":"Demmy T.L.","year":"2012","unstructured":"Demmy TL, Gu L, Burkhalter JE. Optimal management of malignant pleural effusion (result of CALGB 30102).","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1378\/chest.129.6.1556","volume":"129","author":"Feller-Kopman D.","year":"2006","unstructured":"Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis.","journal-title":"Chest"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.athoracsur.2007.06.038","volume":"84","author":"Feller-Kopman D.","year":"2007","unstructured":"Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema.","journal-title":"Ann Thorac Surg"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1378\/chest.126.6.1764","volume":"126","author":"Doelken P.","year":"2004","unstructured":"Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: Technique and clinical implications.","journal-title":"Chest"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archinternmed.2009.548","volume":"170","author":"Gordon C.E.","year":"2010","unstructured":"Gordon CE, Feller-Kopman D, Balk EM. Pneumothorax following thoracentesis: A systematic review and meta-analysis.","journal-title":"Arch Intern Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1164\/rccm.201607-1404OC","volume":"195","author":"Wahidi M.M.","year":"2017","unstructured":"Wahidi MM, Reddy C, Yarmus L. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP Trial.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000342343","volume":"85","author":"Sabur N.F.","year":"2013","unstructured":"Sabur NF, Chee A, Stather DR. The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions.","journal-title":"Respiration"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2017.01.019","volume":"108","author":"Boshuizen R.C.","year":"2017","unstructured":"Boshuizen RC, Vd Noort V, Burgers JA. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14).","journal-title":"Lung Cancer"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2005.05.016","volume":"50","author":"van den Toorn L.M.","year":"2005","unstructured":"van den Toorn LM, Schaap E, Surmont VF. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter.","journal-title":"Lung Cancer"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1378\/chest.129.2.362","volume":"129","author":"Tremblay A.","year":"2006","unstructured":"Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion.","journal-title":"Chest"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.athoracsur.2007.11.039","volume":"85","author":"Warren W.H.","year":"2008","unstructured":"Warren WH, Kalimi R, Khodadadian LM, Kim AW. Management of malignant pleural effusions using the Pleural catheter.","journal-title":"Ann Thorac Surg"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1378\/chest.11-2657","volume":"142","author":"Fysh E.T.","year":"2012","unstructured":"Fysh ET, Waterer GW, Kendall PA. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion.","journal-title":"Chest"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.athoracsur.2012.01.103","volume":"94","author":"Hunt B.M.","year":"2012","unstructured":"Hunt BM, Farivar AS, Valli\u00e8res E. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions.","journal-title":"Ann Thorac Surg"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1378\/chest.12-3103","volume":"144","author":"Fysh E.T.","year":"2013","unstructured":"Fysh ET, Tremblay A, Feller-Kopman D. Clinical outcomes of indwelling pleural catheter-related pleural infections: An international multicenter study.","journal-title":"Chest"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/1817-1737.160837","volume":"10","author":"Rial M.B.","year":"2015","unstructured":"Rial MB, Lamela IP, Fern\u00e1ndez VL. Management of malignant pleural effusion by an indwelling pleural catheter: A cost-efficiency analysis.","journal-title":"Ann Thorac Med"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","volume":"318","author":"Thomas R.","year":"2017","unstructured":"Thomas R, Fysh ETH, Smith NA. Effect of an Indwelling Pleural Catheter Talc Pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial.","journal-title":"JAMA"},{"key":"ref=32","first-page":"1052","volume":"7","author":"Fortin M.","year":"2015","unstructured":"Fortin M, Tremblay A. Pleural controversies: Indwelling pleural catheter . pleurodesis for malignant pleural effusions.","journal-title":"J Thorac Dis"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.athoracsur.2013.03.063","volume":"96","author":"Freeman R.K.","year":"2013","unstructured":"Freeman RK, Ascioti AJ, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy.","journal-title":"Ann Thorac Surg"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1378\/chest.119.6.1641","volume":"119","author":"Pien G.W.","year":"2001","unstructured":"Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.","journal-title":"Chest"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jvir.2010.01.021","volume":"21","author":"Thornton R.H.","year":"2010","unstructured":"Thornton RH, Miller Z, Covey AM. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis.","journal-title":"J Vasc Interv Radiol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1378\/chest.14-2199","volume":"148","author":"Bibby A.C.","year":"2015","unstructured":"Bibby AC, Clive AO, Slade GC. Survival in patients with malignant pleural effusions who developed pleural infection: A retrospective case review from six UK centers.","journal-title":"Chest"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1378\/chest.14-3119","volume":"148","author":"Gilbert C.R.","year":"2015","unstructured":"Gilbert CR, Lee HJ, Skalski JH. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: A multicenter study.","journal-title":"Chest"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0269216314521851","volume":"28","author":"Lorenzo M.J.","year":"2014","unstructured":"Lorenzo MJ, Modesto M, P\u00e9rez J. Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: a prospective study.","journal-title":"Palliat Med"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12890-016-0203-7","volume":"16","author":"Hak C.C.","year":"2016","unstructured":"Hak CC, Sivakumar P, Ahmed L. Safety of indwelling pleural catheter use in patients undergoing chemotherapy: A five-year retrospective evaluation.","journal-title":"BMC Pulm Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1513\/AnnalsATS.201610-785OC","volume":"14","author":"Faiz S.A.","year":"2017","unstructured":"Faiz SA, Pathania P, Song J. Indwelling pleural catheters for patients with hematologic malignancies. A 14-Year, Single-Center experience.","journal-title":"Ann Am Thorac Soc"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1183\/09031936.00164706","volume":"30","author":"Tremblay A.","year":"2007","unstructured":"Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis.","journal-title":"Eur Respir J"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1806-37562016000000021","volume":"43","author":"Abr\u00e3o F.C.","year":"2017","unstructured":"Abr\u00e3o FC, Abreu IR, Cavalcanti MG, Pompa-Filho JF. Use of indwelling pleural catheters for the definitive treatment of malignant pleural effusion.","journal-title":"J Bras Pneumol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1378\/chest.10-1868","volume":"139","author":"Reddy C.","year":"2011","unstructured":"Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: A pilot study.","journal-title":"Chest"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1378\/chest.11-0724","volume":"141","author":"Fysh E.T.","year":"2012","unstructured":"Fysh ET, Wrightson JM, Lee YC, Rahman NM. Fractured indwelling pleural catheters.","journal-title":"Chest"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00063198-200207000-00010","volume":"8","author":"Pollak J.S.","year":"2002","unstructured":"Pollak JS. Malignant pleural effusions: Treatment with tunneled long-term drainage catheters.","journal-title":"Curr Opin Pulm Med"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1051-0443(07)61826-0","volume":"12","author":"Pollak J.S.","year":"2001","unstructured":"Pollak JS, Burdge CM, Rosenblatt M. Treatment of malignant pleural effusions with tunneled long- term drainage catheters.","journal-title":"J Vasc Interv Radiol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1378\/chest.14-0394","volume":"146","author":"Ahmed L.","year":"2014","unstructured":"Ahmed L, Ip H, Rao D. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: Retrospective case series of a novel clinical pathway.","journal-title":"Chest"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1378\/chest.118.2.417","volume":"118","author":"Saffran L.","year":"2000","unstructured":"Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter.","journal-title":"Chest"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1245\/s10434-009-0691-2","volume":"16","author":"Bazerbashi S.","year":"2009","unstructured":"Bazerbashi S, Villaquiran J, Awan MY. Ambulatory intercostal drainage for the management of malignant pleural effusion: A single center experience.","journal-title":"Ann Surg Oncol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0022-5223(19)33712-2","volume":"106","author":"Waissberg D.","year":"1993","unstructured":"Waissberg D, Ben-Zeev I. Talc pleurodesis: Experience with 360 patients.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1010-7940(01)01130-7","volume":"21","author":"Cardillo G.","year":"2002","unstructured":"Cardillo G, Facciolo F, Carbone L. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=52","first-page":"CD002916","volume":"1","author":"Shaw P.","year":"2006","unstructured":"Shaw P, Agarwald R. Pleurodesis for malignant pleural effusions.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","volume":"307","author":"Davies H.E.","year":"2012","unstructured":"Davies HE, Mishra EK, Kahan BC. Effect of an indwelling pleural catheter chest tube and talc pleurodesis for reliving dyspnea in patients with malignant pleural effusion. The TIME2 randomized controlled trail.","journal-title":"JAMA"},{"key":"ref=54","first-page":"CD010529","volume":"5","author":"Clive A.O.","year":"2016","unstructured":"Clive AO, Jones HE, Bhatnagar R. Interventions for the management of malignant pleural effusions: A network meta-analysis.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ejcts.2005.12.025","volume":"29","author":"Tan C.","year":"2006","unstructured":"Tan C, Sedrakyan A, Browne J. The evidence on the effectiveness of management for malignant pleural effusion: A systematic review.","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.athoracsur.2007.02.061","volume":"83","author":"Steger V.","year":"2007","unstructured":"Steger V, Mika U, Toomes H. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.","journal-title":"Ann Thorac Surg"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2008.02.017","volume":"62","author":"Yildirim H.","year":"2008","unstructured":"Yildirim H, Metintas M, Ak G. Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.","journal-title":"Lung Cancer"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1378\/chest.123.6.1895","volume":"123","author":"Spiegler P.A.","year":"2003","unstructured":"Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions.","journal-title":"Chest"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00408-011-9283-6","volume":"189","author":"Bielsa S.","year":"2011","unstructured":"Bielsa S, Hern\u00e1ndez P, Rodriguez-Panadero F. Tumor type influences the effectiveness of pleurodesis in malignant effusions.","journal-title":"Lung"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.127.3.909","volume":"127","author":"Dresler C.M.","year":"2005","unstructured":"Dresler CM, Olak J, Herndon JE. Phase III intergroup study of talc poudrage talc slurry sclerosis for malignant pleural effusion.","journal-title":"Chest"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1716883","volume":"378","author":"Bhatnagar R.","year":"2018","unstructured":"Bhatnagar R, Keenan EK, Morley AJ. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/00015458.2013.11680926","volume":"113","author":"Kara M.","year":"2013","unstructured":"Kara M, Alzafer S, Okur E, Halezeroglu S. The use of single incision thoracoscopic pleurectomy in the management of malignant pleural effusion.","journal-title":"Acta Chir Belg"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejcts.2007.09.039","volume":"33","author":"Nakas A.","year":"2008","unstructured":"Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy\/decortication in the therapeutic management of malignant pleural mesothelioma.","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","volume":"135","author":"Flores R.M.","year":"2008","unstructured":"Flores RM, Pass HI, Seshan VE. Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","volume":"384","author":"Rintoul R.C.","year":"2014","unstructured":"Rintoul RC, Ritchie AJ, Edwards JG. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): An open-label, randomised, controlled trial.","journal-title":"Lancet"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/1097-0142(19950201)75:3<801::AID-CNCR2820750309>3.0.CO;2-H","volume":"75","author":"Petrou M.","year":"1995","unstructured":"Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions: The complimentary role talc pleurodesis and pleuroperitoneal shunting.","journal-title":"Cancer"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1010-7940(00)00422-X","volume":"18","author":"Genc O.","year":"2000","unstructured":"Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jvir.2013.03.012","volume":"24","author":"Khiatani V.","year":"2013","unstructured":"Khiatani V, Isaacson A, Yu H, Stavas J. Interventional radiologic placement of Denver pleuroperitoneal shunt for refractory chylothorax.","journal-title":"J Vasc Interv Radiol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5761\/atcs.cr.09.01482","volume":"17","author":"Shimmyo T.","year":"2011","unstructured":"Shimmyo T, Morita K, Mineshita M. Pleuroperitoneal shunt for chylothorax and chylopericardium in lung cancer: A case report.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JTO.0b013e3181c07ddc","volume":"5","author":"Jones D.R.","year":"2010","unstructured":"Jones DR, Taylor MD, Petroni GR. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion.","journal-title":"J Thorac Oncol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bjc.6603319","volume":"95","author":"Seto T.","year":"2006","unstructured":"Seto T, Ushijima S, Yamamoto H. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: A multi-institutional phase II trial.","journal-title":"Br J Cancer"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.rmed.2013.01.010","volume":"107","author":"I\u015f\u0131k A.F.","year":"2013","unstructured":"I\u015f\u0131k AF, Sanl\u0131 M, Y\u0131lmaz M. Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies.","journal-title":"Respir Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s12094-015-1464-y","volume":"18","author":"Marquez-Medina D.","year":"2016","unstructured":"Marquez-Medina D, Popat S. Closing faucets: The role of anti-angiogenic therapies in malignant pleural diseases.","journal-title":"Clin Transl Oncol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3892\/mco.2014.457","volume":"3","author":"Masago K.","year":"2015","unstructured":"Masago K, Fujimoto D, Fujita S. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.","journal-title":"Mol Clin Oncol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3892\/or.2013.2349","volume":"29","author":"Du N.","year":"2013","unstructured":"Du N, Li X, Li F. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer\u2010mediated malignant pleural effusion.","journal-title":"Oncol Rep"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"J\u00e4nne P.A.","year":"2015","unstructured":"J\u00e4nne PA, Yang JC, Kim DW. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","journal-title":"N Engl J Med"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"Mok T.S.","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","journal-title":"N Engl J Med"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"62648","DOI":"10.18632\/oncotarget.16061","volume":"8","author":"Jiang T.","year":"2017","unstructured":"Jiang T, Li A, Su C. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients.","journal-title":"Oncotarget"},{"key":"ref=79","first-page":"8019","volume":"17","author":"Chen Y.","year":"2018","unstructured":"Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review).","journal-title":"Mol Med Rep"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","volume":"19","author":"Psallidas I.","year":"2018","unstructured":"Psallidas I, Kanellakis NI, Gerry S. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): A multicohort analysis.","journal-title":"Lancet Oncol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"Clive A.O.","year":"2014","unstructured":"Clive AO, Kahan BC, Hooper CE. Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score.","journal-title":"Thorax"},{"key":"ref=82","author":"Abrao F.","unstructured":"Abrao F, Campello de Oliveira M. Prognostic factors for mortality in malignant pleural effusion: Is it possible to predict survival?\u201d. Proc ASCO 2017; 35(suppl 15): Abst. e21638"},{"key":"ref=83","author":"Heffner JE","year":"2018","unstructured":"Heffner JE.","journal-title":"Management of malignant pleural effusions UpToDate"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T18:36:22Z","timestamp":1605551782000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168009\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574887114666181204105208","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}